MTAAPHN
Market cap549mUSD
Dec 20, Last price
54.60EUR
1D
1.68%
1Q
-5.04%
IPO
294.22%
Name
Pharmanutra SpA
Chart & Performance
P/E
41.03
P/S
5.25
EPS
1.33
Div Yield, %
1.47%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
16.51%
Revenues
101m
+21.15%
Net income
13m
-14.73%
CFO
12m
-16.41%
Dividend
May 06, 20240.85 EUR/sh
Profile
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 101,034 21.15% | 83,394 21.60% | 68,578 17.27% | ||||||
Cost of revenue | 75,803 | 84,899 | 69,760 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 25,231 | (1,505) | (1,182) | ||||||
NOPBT Margin | 24.97% | ||||||||
Operating Taxes | 10,428 | 8,370 | 5,038 | ||||||
Tax Rate | 41.33% | ||||||||
NOPAT | 14,803 | (9,875) | (6,220) | ||||||
Net income | 12,832 -14.73% | 15,048 9.27% | 13,771 -2.14% | ||||||
Dividends | (7,714) | (6,852) | (6,486) | ||||||
Dividend yield | 1.41% | 1.14% | 0.89% | ||||||
Proceeds from repurchase of equity | (1,651) | (2,331) | |||||||
BB yield | 0.30% | 0.39% | |||||||
| Debt | |||||||||
Debt current | 4,585 | 3,616 | 820 | ||||||
Long-term debt | 25,042 | 14,859 | 6,313 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 6,958 | 9,307 | 4,000 | ||||||
Net debt | 4,297 | (3,580) | (22,530) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 12,092 | 14,466 | 20,413 | ||||||
CAPEX | (13,249) | (23,157) | (4,987) | ||||||
Cash from investing activities | (14,702) | (23,715) | (5,543) | ||||||
Cash from financing activities | (516) | 1,891 | (1,916) | ||||||
FCF | 2,519 | (22,742) | (6,224) | ||||||
| Balance | |||||||||
Cash | 25,118 | 26,861 | 33,939 | ||||||
Long term investments | 212 | (4,806) | (4,276) | ||||||
Excess cash | 20,278 | 17,885 | 26,234 | ||||||
Stockholders' equity | 54,407 | 68,358 | 58,853 | ||||||
Invested Capital | 69,102 | 58,572 | 25,765 | ||||||
ROIC | 23.19% | ||||||||
ROCE | 28.23% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 9,668 | 9,672 | 9,681 | ||||||
Price | 56.40 -9.47% | 62.30 -17.37% | 75.40 100.53% | ||||||
Market cap | 545,255 -9.51% | 602,573 -17.45% | 729,946 100.53% | ||||||
EV | 549,552 | 598,993 | 707,416 | ||||||
EBITDA | 27,648 | (361) | 207 | ||||||
EV/EBITDA | 19.88 | 3,417.47 | |||||||
Interest | 802 | 60 | 19 | ||||||
Interest/NOPBT | 3.18% | ||||||||